Cargando…

Validation of the Rome proposal for severity of acute exacerbation of chronic obstructive pulmonary disease

BACKGROUND: The Rome proposal provides an objective assessment tool for severity of acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) but requires validation. OBJECTIVES: We aimed to evaluate the predictive performance of the Rome proposal in patients with AE-COPD. DESIGN: This o...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Hyo Jin, Lee, Jung-Kyu, Park, Tae Yun, Heo, Eun Young, Kim, Deog Kyeom, Lee, Hyun Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10286168/
https://www.ncbi.nlm.nih.gov/pubmed/37338152
http://dx.doi.org/10.1177/17534666231172917
Descripción
Sumario:BACKGROUND: The Rome proposal provides an objective assessment tool for severity of acute exacerbation of chronic obstructive pulmonary disease (AE-COPD) but requires validation. OBJECTIVES: We aimed to evaluate the predictive performance of the Rome proposal in patients with AE-COPD. DESIGN: This observational study assessed the patients who visited the emergency room (ER) or were hospitalized due to AE-COPD between January 2010 and December 2020. METHODS: We compared the performance of the Rome Proposal with that of the DECAF score or GesEPOC 2021 criteria in predicting intensive care unit (ICU) admission, need for non-invasive ventilation (NIV) or invasive mechanical ventilation (IMV), and in-hospital mortality. RESULTS: A total of 740 events of ER visit or hospitalization due to AE-COPD were reviewed and classified into mild (30.9%), moderate (58.6%), or severe (10.4%) group according to the Rome proposal. The severe group had a higher rate of ICU admission, required more NIV or IMV, and had a higher in-hospital mortality than the mild and moderate groups. The predictive performance of the Rome proposal was significantly better for ICU admission [area under the receiver operating characteristic curve (AU-ROC) = 0.850 versus 0.736, p = 0.004] and need for NIV or IMV (AU-ROC = 0.870 versus 0.770, p = 0.004) than that of the GesEPOC 2021 criteria but better than that of the DECAF score only in female patients. There was no significant difference in predicting the in-hospital mortality between the Rome proposal and DECAF score or GesEPOC 2021 criteria. CONCLUSION: External validation of the Rome Proposal in Korean patients demonstrated excellent performance for ICU admission and need for NIV or IMV and an acceptable performance for in-hospital mortality.